s**********9
发帖数: 846 | 1 This report is being posted at this time for subscribers only.
Shares of Radient Pharmaceuticals Corp. (AMEX: RPC ) are breaking out and
should see significant appreciation in the coming weeks as the AMEX is
rumored to be approving the company's recently board approved and announced
debt-to-equity exchange. Shareholder votes at its Annual Meeting of
Shareholders (held Friday, December 3, 2010) were in favor of the execution
of a financial stabilization plan that should take company from tens of
millions of dollars in debt to close to $30 million in equity. The company
submited all of the approved proposals and related issuances to the NYSE
Amex for their approval and word of that approval could come within days.
Radient Pharmaceuticals
0.47 +0.10 (+28.21%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
In addition, the company is expecting positive news from the Mayo Clinic in
regards to a clinical study for the validation of RPC’s US FDA‐approved
Onko‐Sure in vitro diagnostic (IVD) cancer test for lung cancer. Results
from that validation are rumored to be "only a couple of weeks away."
The stock has traded between $0.20 and $2.59 this year and we feel these
news items will cause shares to appreciate significantly from these levels
as the company has been busy making news on other fronts in recent days.
Furthermore, we expect that increased foreign sales and additional revenue
of the Onko‐Sure cancer test will continue and also be announced in the
coming weeks.
A report about these developments to the rest of our readership and news
distribution outlets will follow.
Read the full report: http://biomedreports.com/2010122061624/trade-alert-approval-should-send-shares-higher.html#ixzz18gBI8vcW | s**********9
发帖数: 846 | 2 Any one follow it.
it was 0.47 when I posted it, now it is 0.57 | M*P
发帖数: 6456 | 3 good job, nice post for DT.
announced
execution
【在 s**********9 的大作中提到】
: This report is being posted at this time for subscribers only.
: Shares of Radient Pharmaceuticals Corp. (AMEX: RPC ) are breaking out and
: should see significant appreciation in the coming weeks as the AMEX is
: rumored to be approving the company's recently board approved and announced
: debt-to-equity exchange. Shareholder votes at its Annual Meeting of
: Shareholders (held Friday, December 3, 2010) were in favor of the execution
: of a financial stabilization plan that should take company from tens of
: millions of dollars in debt to close to $30 million in equity. The company
: submited all of the approved proposals and related issuances to the NYSE
: Amex for their approval and word of that approval could come within days.
| s**********9
发帖数: 846 | 4 Agree. out at 0.67.
【在 M*P 的大作中提到】
: good job, nice post for DT.
:
: announced
: execution
| p********e
发帖数: 1960 | | s*****e
发帖数: 1368 | | s**********9
发帖数: 846 | 7 This is crazy, no real new. only pump. | s**********9
发帖数: 846 | 8 This another subscriber only info: it is not as excited as RPC
It appears the long-awaited PHASE III trials for Cel-Sci's Multikine are
officially open, although we have not seen any official announcement from
the company.
Perhaps they are waiting until there are more people back in the market (
this week is traditionally slow) before they officially announce something
via an official press release. The company does have a number of days
grnted to them before they announce a material event.
Have a look at this newly posted information: http://www.clinicaltrials.gov/ct2/show/NCT01265849?lead=cel-sci&rank=1
Just days ago, the company announced that it had received governmental
approval from the Health Authority, Ministry of Health of Ukraine, to begin
enrollment of subjects for the Phase III clinical trial of Multikine in
theUkraine, but nothing noting this new Dec 22nd development has been posted
by the company.
Multikine is the Company’s flagship immunotherapy developed as a first-line
standard of care in treating head and neck cancer.
Phase II clinical trials of Multikine demonstrated the product was safe and
well-tolerated and eliminated tumors in 12% of the subjects less than a
month into treatment. The Multikine treatment regimen was also shown to kill
, on average, about half of the cancer cells in the subjects’ tumors before
the start of standard therapy. Follow-up studies of subjects enrolled in
Phase II trials showed a 33% improvement in the survival rate of those
treated with Multikine at a median of three and a half years following
surgery. The U.S. Food and Drug Administration granted orphan drug status to
Multikine in the neoadjuvant therapy of patients with squamous cell
carcinoma of the head and neck. | p********e
发帖数: 1960 | | s**********9
发帖数: 846 | 10 Notebook: Just when they thought it was safe to go short
PDF | Print | E-mail
Written by M.E.Garza
Tuesday, 28 December 2010 13:58
0diggsdigg
This report is being posted for subscribers only.
Radient Pharmaceuticals
0.91 -0.07 (-7.44%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
In early trading it looks like the naked shorts have once again attempted to
knock down shares of Radient Pharmaceuticals (AMEX:RPC). The stock saw lows
of $0.79 after holding strong at the $1 level during during Monday's
session, but it refuses to stay down. The lower prices didn't last long as
longs came in to scoop up even more.
Just when they thought it was safe to go short, it appears a new analyst
report with a $4 price target near term and a $15-$20 long term price target
is circulating, but apparenlty not yet on the newswires.
The report, prepared by Len Bogner, President of Bogner Business Associates
LLC is even more bullish than previous reports and I'm sure shares will be
impacted once news spreads.
Be on the look-out for it.
Disclosure: Long RPC
Read the full report: http://biomedreports.com/2010122861817/notebook-just-when-they-thought-it-was-safe-to-go-short.html#ixzz19R4evqk9 | | | s**********9
发帖数: 846 | | a*****h
发帖数: 484 | 12 It is so bloody!
【在 s**********9 的大作中提到】
: Dumping!
| f******k
发帖数: 87 | 13 oh, it is my ex, in at 0.73 | s**********9
发帖数: 846 | 14 Biomedreport is pumping it again.
Pending news and rumor update
PDF | Print | E-mail
Written by M.E.Garza
Monday, 10 January 2011 00:28
0diggsdigg
This article is being posted for premium subscribers only.
First of all let me say that last Friday's action on Radient Pharmaceuticals
(Amex:RPC) after shares got halted left us all stunned.Just the fact that
the stock had so much volume, momentum and that shares were going crazy like
that in the morning really surprised us. We were on the phone calling
everyone trying to find out why the Amex halted the shares that way.
If you haven't done so yet, please read my latest report on the company and
what happened on Friday.
It is on the front page and titled: Did panic after halt cause Radient
shares to drop too far?
Read it and please understand one thing. Our reputation is far too important
for us to mis-lead our readers- and in particular- our paid subscribers.
Soon, we will have some very exciting news to share with you about
developments that will cast the brightest light on us yet. Our reach is
about to increase dramatically and that only adds to the sense of
responsibility we feel for our readers.
No one is ever 100% correct on Wall Street, but obviously we have a better
track record and trading system than most. That's why people want to partner
and carry our content more than ever. Let me also make something esle very
clear: We aren't in ANYBODY'S POCKETS! We are accountable to you, to the
authorities and to our own conscience. That is more than we can say about
most of the clowns and ego-maniacs that cover biotech and small-cap stocks
out there. This is no game, just ask the SEC, FCC and other authorities who
oversee our activities and news flow.
What we do is quite simple. We look for companies that we feel have:
1- Upcoming milestones or catalysts that will cause prices to rise in
anticipation of those news events
2- Companies who have interesting stories and offer good propositions for
investors.
Some of those companies are great trades and nothing else. Others present a
great case for becoming a terrific longer-term investment.
As you know from our disclosures, we often invest in the companies we cover
and like. We are bulls at heart and thus believe that naked shorting- in
particular- should be outlawed; just as it is in European markets. It hurts
companies and legitimate investors greatly and that is well documented time
and again. We're not interested. Sorry.
RPC is a stock that we started covering at $.30. It went up as high as $1.70
and we fully believe (as do many other analysts) that it will do higher.
For now, here it is - a much better, healthier company with zero-debt, great
new cap structure, millions in revenues due this year and more shareholder
equity than was anticipated-- all at the bargain price of $.80.
As a trade vehicle, the stock has forward looking news due this week and
more eye-balls than ever watching it.
Did we have something to do with that? Maybe. I refuse to think that we
truly have that much influence over the markets- at least not yet. After all
, we're talking about 41 million shares trading on Friday. That being said,
we know that a vast many of those shares were the tens of millions of naked
shorts who managed to hold out and then were handed a gift on Friday. They
got to cover at lower prices, but still not as low as the $.30-$.40 prices
they shorted the stock at to begin with.
As of this publication we are hearing that the company may release
preliminary data about the key Mayo Clinic validation study within 48 hours.
The results are past due and we thought they might release (at least the
preliminary results) on Monday, but we're hearing from multiple sources that
the news will likely come Tuesday. That's an opportunity for our readers to
make a good trade. If you don't yet understand what the implications are,
please read the article I referrenced above.
We can't tell you to buy or sell a stock. We can only report the stories/
rumors/catalysts as we investigate and find out about them. We can tell you
if a stock is acting bullish or bearish we can advise you when you might
consider taking profits, and we certainly can't tell you to press that
button and make the trade.
We hope you are making money with our FDA Calayst Calendar. We hope that you
find value in our analysis and coverage of this incredibly volatile sector
and we certainly will continue to keep you updated to the best of our
ability.
And speaking of that we are chasing a big rumor involving a defense/biotech
play that we've covered here before. I want to confirm a couple of details
on Monday, but should have something to report by Tuesday at the latest. We'
ll keep you posted.
Related articles
* Radient Pharmaceuticals Traded with Remarkable Volume - RPC - Stock
Bling (news.google.com)
* Interview with the CEO of Radient Pharmaceuticals (AMEX:RPC) (
biomedreports.com)
* Radient Positioned To Deliver Significant Cancer Test Profits Via
Foreign Markets (biomedreports.com)
Disclosure: Long RPC
Read the full report: http://biomedreports.com/2011011062200/important-news-and-rumor-update.html#ixzz1Ae50nMrf | s**********9
发帖数: 846 | 15 Nice!
【在 f******k 的大作中提到】
: oh, it is my ex, in at 0.73
| s**********9
发帖数: 846 | 16 This report is being posted at this time for subscribers only.
Shares of Radient Pharmaceuticals Corp. (AMEX: RPC ) are breaking out and
should see significant appreciation in the coming weeks as the AMEX is
rumored to be approving the company's recently board approved and announced
debt-to-equity exchange. Shareholder votes at its Annual Meeting of
Shareholders (held Friday, December 3, 2010) were in favor of the execution
of a financial stabilization plan that should take company from tens of
millions of dollars in debt to close to $30 million in equity. The company
submited all of the approved proposals and related issuances to the NYSE
Amex for their approval and word of that approval could come within days.
Radient Pharmaceuticals
0.47 +0.10 (+28.21%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
In addition, the company is expecting positive news from the Mayo Clinic in
regards to a clinical study for the validation of RPC’s US FDA‐approved
Onko‐Sure in vitro diagnostic (IVD) cancer test for lung cancer. Results
from that validation are rumored to be "only a couple of weeks away."
The stock has traded between $0.20 and $2.59 this year and we feel these
news items will cause shares to appreciate significantly from these levels
as the company has been busy making news on other fronts in recent days.
Furthermore, we expect that increased foreign sales and additional revenue
of the Onko‐Sure cancer test will continue and also be announced in the
coming weeks.
A report about these developments to the rest of our readership and news
distribution outlets will follow.
Read the full report: http://biomedreports.com/2010122061624/trade-alert-approval-should-send-shares-higher.html#ixzz18gBI8vcW | s**********9
发帖数: 846 | 17 Any one follow it.
it was 0.47 when I posted it, now it is 0.57 | M*P
发帖数: 6456 | 18 good job, nice post for DT.
announced
execution
【在 s**********9 的大作中提到】
: This report is being posted at this time for subscribers only.
: Shares of Radient Pharmaceuticals Corp. (AMEX: RPC ) are breaking out and
: should see significant appreciation in the coming weeks as the AMEX is
: rumored to be approving the company's recently board approved and announced
: debt-to-equity exchange. Shareholder votes at its Annual Meeting of
: Shareholders (held Friday, December 3, 2010) were in favor of the execution
: of a financial stabilization plan that should take company from tens of
: millions of dollars in debt to close to $30 million in equity. The company
: submited all of the approved proposals and related issuances to the NYSE
: Amex for their approval and word of that approval could come within days.
| s**********9
发帖数: 846 | 19 Agree. out at 0.67.
【在 M*P 的大作中提到】
: good job, nice post for DT.
:
: announced
: execution
| p********e
发帖数: 1960 | | | | s*****e
发帖数: 1368 | | s**********9
发帖数: 846 | 22 This is crazy, no real new. only pump. | s**********9
发帖数: 846 | 23 This another subscriber only info: it is not as excited as RPC
It appears the long-awaited PHASE III trials for Cel-Sci's Multikine are
officially open, although we have not seen any official announcement from
the company.
Perhaps they are waiting until there are more people back in the market (
this week is traditionally slow) before they officially announce something
via an official press release. The company does have a number of days
grnted to them before they announce a material event.
Have a look at this newly posted information: http://www.clinicaltrials.gov/ct2/show/NCT01265849?lead=cel-sci&rank=1
Just days ago, the company announced that it had received governmental
approval from the Health Authority, Ministry of Health of Ukraine, to begin
enrollment of subjects for the Phase III clinical trial of Multikine in
theUkraine, but nothing noting this new Dec 22nd development has been posted
by the company.
Multikine is the Company’s flagship immunotherapy developed as a first-line
standard of care in treating head and neck cancer.
Phase II clinical trials of Multikine demonstrated the product was safe and
well-tolerated and eliminated tumors in 12% of the subjects less than a
month into treatment. The Multikine treatment regimen was also shown to kill
, on average, about half of the cancer cells in the subjects’ tumors before
the start of standard therapy. Follow-up studies of subjects enrolled in
Phase II trials showed a 33% improvement in the survival rate of those
treated with Multikine at a median of three and a half years following
surgery. The U.S. Food and Drug Administration granted orphan drug status to
Multikine in the neoadjuvant therapy of patients with squamous cell
carcinoma of the head and neck. | p********e
发帖数: 1960 | | s**********9
发帖数: 846 | 25 Notebook: Just when they thought it was safe to go short
PDF | Print | E-mail
Written by M.E.Garza
Tuesday, 28 December 2010 13:58
0diggsdigg
This report is being posted for subscribers only.
Radient Pharmaceuticals
0.91 -0.07 (-7.44%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
In early trading it looks like the naked shorts have once again attempted to
knock down shares of Radient Pharmaceuticals (AMEX:RPC). The stock saw lows
of $0.79 after holding strong at the $1 level during during Monday's
session, but it refuses to stay down. The lower prices didn't last long as
longs came in to scoop up even more.
Just when they thought it was safe to go short, it appears a new analyst
report with a $4 price target near term and a $15-$20 long term price target
is circulating, but apparenlty not yet on the newswires.
The report, prepared by Len Bogner, President of Bogner Business Associates
LLC is even more bullish than previous reports and I'm sure shares will be
impacted once news spreads.
Be on the look-out for it.
Disclosure: Long RPC
Read the full report: http://biomedreports.com/2010122861817/notebook-just-when-they-thought-it-was-safe-to-go-short.html#ixzz19R4evqk9 | s**********9
发帖数: 846 | | a*****h
发帖数: 484 | 27 It is so bloody!
【在 s**********9 的大作中提到】
: Dumping!
| f******k
发帖数: 87 | 28 oh, it is my ex, in at 0.73 | s**********9
发帖数: 846 | 29 Biomedreport is pumping it again.
Pending news and rumor update
PDF | Print | E-mail
Written by M.E.Garza
Monday, 10 January 2011 00:28
0diggsdigg
This article is being posted for premium subscribers only.
First of all let me say that last Friday's action on Radient Pharmaceuticals
(Amex:RPC) after shares got halted left us all stunned.Just the fact that
the stock had so much volume, momentum and that shares were going crazy like
that in the morning really surprised us. We were on the phone calling
everyone trying to find out why the Amex halted the shares that way.
If you haven't done so yet, please read my latest report on the company and
what happened on Friday.
It is on the front page and titled: Did panic after halt cause Radient
shares to drop too far?
Read it and please understand one thing. Our reputation is far too important
for us to mis-lead our readers- and in particular- our paid subscribers.
Soon, we will have some very exciting news to share with you about
developments that will cast the brightest light on us yet. Our reach is
about to increase dramatically and that only adds to the sense of
responsibility we feel for our readers.
No one is ever 100% correct on Wall Street, but obviously we have a better
track record and trading system than most. That's why people want to partner
and carry our content more than ever. Let me also make something esle very
clear: We aren't in ANYBODY'S POCKETS! We are accountable to you, to the
authorities and to our own conscience. That is more than we can say about
most of the clowns and ego-maniacs that cover biotech and small-cap stocks
out there. This is no game, just ask the SEC, FCC and other authorities who
oversee our activities and news flow.
What we do is quite simple. We look for companies that we feel have:
1- Upcoming milestones or catalysts that will cause prices to rise in
anticipation of those news events
2- Companies who have interesting stories and offer good propositions for
investors.
Some of those companies are great trades and nothing else. Others present a
great case for becoming a terrific longer-term investment.
As you know from our disclosures, we often invest in the companies we cover
and like. We are bulls at heart and thus believe that naked shorting- in
particular- should be outlawed; just as it is in European markets. It hurts
companies and legitimate investors greatly and that is well documented time
and again. We're not interested. Sorry.
RPC is a stock that we started covering at $.30. It went up as high as $1.70
and we fully believe (as do many other analysts) that it will do higher.
For now, here it is - a much better, healthier company with zero-debt, great
new cap structure, millions in revenues due this year and more shareholder
equity than was anticipated-- all at the bargain price of $.80.
As a trade vehicle, the stock has forward looking news due this week and
more eye-balls than ever watching it.
Did we have something to do with that? Maybe. I refuse to think that we
truly have that much influence over the markets- at least not yet. After all
, we're talking about 41 million shares trading on Friday. That being said,
we know that a vast many of those shares were the tens of millions of naked
shorts who managed to hold out and then were handed a gift on Friday. They
got to cover at lower prices, but still not as low as the $.30-$.40 prices
they shorted the stock at to begin with.
As of this publication we are hearing that the company may release
preliminary data about the key Mayo Clinic validation study within 48 hours.
The results are past due and we thought they might release (at least the
preliminary results) on Monday, but we're hearing from multiple sources that
the news will likely come Tuesday. That's an opportunity for our readers to
make a good trade. If you don't yet understand what the implications are,
please read the article I referrenced above.
We can't tell you to buy or sell a stock. We can only report the stories/
rumors/catalysts as we investigate and find out about them. We can tell you
if a stock is acting bullish or bearish we can advise you when you might
consider taking profits, and we certainly can't tell you to press that
button and make the trade.
We hope you are making money with our FDA Calayst Calendar. We hope that you
find value in our analysis and coverage of this incredibly volatile sector
and we certainly will continue to keep you updated to the best of our
ability.
And speaking of that we are chasing a big rumor involving a defense/biotech
play that we've covered here before. I want to confirm a couple of details
on Monday, but should have something to report by Tuesday at the latest. We'
ll keep you posted.
Related articles
* Radient Pharmaceuticals Traded with Remarkable Volume - RPC - Stock
Bling (news.google.com)
* Interview with the CEO of Radient Pharmaceuticals (AMEX:RPC) (
biomedreports.com)
* Radient Positioned To Deliver Significant Cancer Test Profits Via
Foreign Markets (biomedreports.com)
Disclosure: Long RPC
Read the full report: http://biomedreports.com/2011011062200/important-news-and-rumor-update.html#ixzz1Ae50nMrf | s**********9
发帖数: 846 | 30 Nice!
【在 f******k 的大作中提到】
: oh, it is my ex, in at 0.73
|
|
